160 results about "Ischemic reperfusion injury" patented technology

The present invention provides a method of post-conditioning reperfusion of an organ or tissue injured by ischemia. Also provided is a method of treating a myocardial infarction in a subject to prevent injury to the heart following reperfusion of the heart.

Disclosed herein are formulations of nitrite, nitrite salt, or nitrite- or nitric oxide-producing compounds suitable for aerosolization and use of such formulations for aerosol administration of nitrite, nitrite salt, or nitrite- or nitric oxide-donating compounds for the treatment of pulmonary arterial hypertension, intra-nasal or pulmonary bacterial infections, or to treat or prevent ischemic reperfusion injury of the heart, brain and organs involved in transplantation. In particular, inhaled nitrite, nitrite salt, or nitrite- or nitric oxide-donating compound specifically formulated and delivered to the respiratory tract for the indications is described. Compositions include all formulations, kits, and device combinations described herein. Methods include inhalation procedures and manufacturing processes for production and use of the compositions described.

The invention provides methods and compositions for treating or preventing ischemic reperfusion injury. The methods of the instant invention comprise the administration of compositions comprising apolipoproteins, lecithin cholesterol acyltransferase or paraoxonase and lipid complexes thereof to treat, reduce or prevent ischemic reperfusion injury.

A method of treating ischemic reperfusion injury in a subject. The method may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. The pharmaceutically acceptable formulation may include a synthetic analog or derivative of a carotenoid. The subject may be administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include a cyclic ring including at least one substituent. In some embodiments, a cyclic ring of a carotenoid analog or derivative may include at least one substituent. The substituent may be coupled to the cyclic ring with an ester functionality.

A postconditioning method and system for preventing injury to an organ or tissue in a subject during or after reperfusion following an ischemic event to the organ or tissue. The system can exemplarily include a catheter configured for insertion therein a vessel of the subject; a means for modulating the flow of fluid within the vessel of the subject; and a control system in communication with the means for modulating the flow of fluid configured to control pulsation of the flow of fluid within the vessel for a desired period of time and at a desired pulsatile frequency.

A method of treating ischemic reperfusion injury in a subject. The method may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. The pharmaceutically acceptable formulation may include a synthetic analog or derivative of a carotenoid. The subject may be administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include an acyclic alkene including at least one substituent and/or a cyclic ring including at least one substituent. In some embodiments, a carotenoid analog or derivative may include at least one substituent.

The present invention provides one new kind of glycyrrhetic acid derivative with high water solubility, high absorption, no irritation to blood vessel and capacity of being prepared into injection, and its preparation process, medicinal composition and preparation. The glycyrrhetic acid derivative has excellent treating effect on acute and chronic hepatitis, bacterial hepatitis, viral hepatitis, cerebral ischemia/re-perfusion damage, brain injury and myocardial ischemia/re-perfusion damage.

The present disclosure relates to a composition for treating and preventing an ischemic injury. More particularly, it relates to a composition containing a peptide derived from a telomerase, which is effective in treating and preventing an ischemic injury. The peptide according to the present disclosure, a peptide having 80% or more sequence identity with the amino acid sequence of the peptide or a peptide which is a fragment thereof, has a superior effect of treating and preventing an ischemic injury. Accordingly, a composition containing the peptide may be effectively used for an ischemic injury, particularly for an ischemic-reperfusion injury.

Hepatic ischemic reperfusion injury is a major complication of liver transplantation, resectional hepatic surgeries, trauma surgery and shock. Disclosed herein are methods for the prevention and treatment of ischemia and reperfusion injury with the administration of sulfatides. Also disclosed herein are methods of preventing and treating hepatic reperfusion injury by administering an amount of a sulfatide to the body of a patient effective to reduce or prevent the symptoms of the injury.

The present invention encompasses the use of compounds for a novel approach to treat and prevent diseases, conditions, and disorders such as diabetes and ischemic reperfusion injury. Compounds of the invention, including but not limited to BAM15((2-fluorophenyl){6-[(2-fluorophenyl)amino](1,2,5-oxadiazolo[3,4-e]pyrazin-5-yl)}amine), a mitochondrial uncoupler, can improve glucose tolerance, increases cellular oxygen consumption, treat or prevent kidney ischemia reperfusion injury reverse insulin resistance, reverse or treat hyperinsulinemia, and reverse or treat hyperlipidemia. The present invention further provides novel compounds as well as methods for identifying compounds with the same or similar properties as BAM15.

A process for making nanoparticles of biocompatible materials is described, wherein an aqueous reaction mixture comprising cerous ion, citric acid and ethylenediaminetetraacetic acid in a predetermined ratio, an oxidant, and water is provided along with temperature conditions to directly form, without isolation, a stable dispersion of cerium oxide nanoparticles. These biocompatible cerium oxide nanoparticles may be used to prevent and/or treat oxidative stress related diseases, such as stroke, relapse/remitting multiple sclerosis, chronic-progressive multiple sclerosis, amyotrophic lateral sclerosis, and ischemic reperfusion injury.

The present invention provides one kind of total paeonoside extract and its preparation process as well as the application of the total paeonoside extract in preparing medicine for preventing and treating cardiac and cerebral vascular diseases. Specifically, the total paeonoside extract is used in preparing medicine for preventing and treating cerebral apoplexy, cerebral ischemia/re-perfusion damabe, brain trauma, senile dementia, etc.

The present invention relates to a medicament comprising the compound of formula (I)

wherein all symbols have the same meanings as defined in the specification, a salt thereof or a prodrug thereof. The compound of the present invention is useful for the prevention and/or treatment of immune diseases such as various types of inflammation, autoimmune disease, allergic diseases, etc.; infection concerning inflammation or HIV infections (e.g. asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, ulcerative colitis, etc.), organ transplantation rejection, immunosuppression, psoriasis, multiple sclerosis, optic neuritis, polymyalgia rheumatica syndrome, uveitis, vasculitis, human immunodeficiency virus infection (acquired immunodeficiency syndrome etc.), atopic dermatitis, urticaria, allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis, osteoarthritis, ischemic reperfusion injury, acute respiratory distress syndrome, shock accompanying bacteria infection, diabetes, cancer metastasis, atherosclerosis, etc.).

The present invention discloses a preparation method for a novel red blood cell substitute-artificial red blood cell fluorescent nanoparticles. According to the present invention, a cross-linking technology is adopted to carry out a cross-linking reaction for hemoglobin (Hb), catalase (CAT), superoxide dismutase (SOD) and carbonic anhydrase (CA) to generate a polyHb-SOD-CAT-CA complex body, wherein the cross-linking technology is performed by a bifunctional reagent glutaraldehyde; the polyHb-SOD-CAT-CA complex body is further embedded by polylactic acid and polyethylene glycol copolymer (PLA-PEG) nanoparticles. With the present invention, the antioxidase of the SOD and the CAT in the complex body can eliminate the oxygen free radicals generated during the blood transfusion process, such that the ischemia-reperfusion injury easily generated during the blood replacement process can be avoided; with the CA, the red blood cell substitute of the present invention has oxygen carrying performance and carbon dioxide transportation performance; with the PLA-PEG microcapsule embedding, the half life period of the artificial blood product can be prolonged, the biocompatibility of the artificial blood product can be increased.

The invention discloses a compound as shown in the structural general formula (I), wherein R is a substituent or double substituents and is independently selected from NO2, OH, OCH3, halogen and H. The compound is used for treating ischemia reperfusion injury. The compound is simple and convenient in synthesis method; and a molecule of the compound contains a structural unit of the free radical of nitroxide to ensure that free radical can be removed efficiently and circularly, and the compound has a remarkable inhibiting effect on ischemia reperfusion injury, so that the compound has important practical values.